Phase-2B / Phase-3 *ETHYL CERVONATE is a trademark of Sancilio & Company, Inc.
A New Paradigm in Sickle Cell Disease Treatment for Children through a Proprietary Platform for Enhanced Absorption of Lipophilic Drugs.
SC411 is an investigational drug that uses ALT designed to prevent painful crises in Sickle Cell Disease patients.
SC411 Product Benefits
The largest study ever conducted in support that Omega-3 is safe and well tolerated in patients with Sickle Cell Disease
Studies show that Omega-3 helps Sickle Cell patients achieve significant and sustained reduction in painful crises, along with significant improvement in anemia with a reduction in the need for blood transfusions
Children with Sickle Cell Disease who took Omega-3 had fewer absences in school and overall better attendance than children with Sickle Cell Disease who did not take Omega-3
U.S. Orphan Drug Designation granted April 2015
FDA pre-IND meeting completed
Pivotal clinical protocol reviewed by FDA
IND filed and accepted by FDA in December of 2015